ARTICLE | Clinical News

Plazomicin: Phase III started

September 22, 2014 7:00 AM UTC

Achaogen enrolled the first patient in an open-label, international Phase III trial comparing IV plazomicin plus meropenem or tigecycline vs. IV colistin plus meropenem or tigecycline in about 360 patients with bloodstream infection or nosocomial pneumonia due to CRE. The company has an SPA from FDA for the trial. Plazomicin has Fast Track designation in the U.S. to treat serious and life-threatening CRE infections. ...